Influence of Primary Pancreatic Tumor Location on Efficacy and Treatment Exposure in the Mpact Trial of Nab-Paclitaxel (Nab-P) Plus Gemcitabine (Gem) Vs Gem Alone for Patients with Metastatic Pancreatic Cancer (Mpc)
Wen Ma(Southern Medical University), Daniel D. Von Hoff(Translational Genomics Research Institute), Stefano Ferrara(Bristol-Myers Squibb (Switzerland)), Brian Lu, Hagen F. Kennecke(Oregon Health & Science University), Michele Stanislaw Milella(University of Verona), Darryl Penenberg(Progenics Pharmaceuticals (United States)), Christos S. Karapetis(Clínica Alemana), José A. López-Martín(Research Institute Hospital 12 de Octubre), Diane Prager(Johns Hopkins University), P Balcke(University of Vienna), F. Warren Nugent(Lahey Hospital and Medical Center), Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin)
Cited by 0
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k